AURA (AURA) Stock Price & Analysis
AURA (AURA) fell 0.27% to USD 7.34 as of September 9, 2026 at 14:05 UTC, according to Nexqual real-time market data.
AURA last closed at USD 7.34; the session ranged USD 7.27–7.38 on volume of 52,055 shares. Market capitalization is —, with a 52-week range of USD 4.73–9.54 (NGM). Source: Nexqual, September 9, 2026 at 14:05 UTC.
Key Statistics (as of September 9, 2026 at 14:05 UTC)
| Price | USD 7.34 |
|---|---|
| Change | ▼ 0.27% (down) |
| Previous Close | USD 7.34 |
| Open | USD 7.34 |
| Day Range | USD 7.27 – 7.38 |
| 52-Week Range | USD 4.73 – 9.54 |
| Volume | 52,055 shares |
| Market Cap | — |
| Exchange | NGM |
Technical Analysis (AURA)
Nexqual's technical model rates AURA "STRONG SELL" based on 0 bullish and 5 bearish signals across 128 daily candles, as of September 9, 2026 at 14:05 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 46.48 (neutral) |
| vs SMA50 | Below (USD 7.35) |
| MACD | -0.01 (negative) |
From AURA's Latest SEC 10-K Filing (filed 2026-03-30)
Source: SEC EDGAR 10-K. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| TRDA | Entrada Therapeutics, Inc. | USD 7.48 | ▲ 4.91% |
| JBIO | Jade Biosciences, Inc. | USD 19.72 | ▼ 0.9% |
| TYRA | Tyra Biosciences, Inc. | USD 20.67 | ▼ 27.85% |
| DSGN | Design Therapeutics, Inc. | USD 15.36 | ▲ 1.45% |
| CGEM | Cullinan Therapeutics, Inc. | USD 21.62 | ▼ 2.13% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 9, 2026 at 14:05 UTC. This page is informational and not investment advice.